Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Share Price

Equities

002932

CNE1000033Q7

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
19.59 CNY -1.61% Intraday chart for Wuhan Easy Diagnosis Biomedicine Co.,Ltd. -2.05% -14.71%

Financials

Sales 2021 2.83B 391M 31.17B Sales 2022 10.53B 1.45B 116B Capitalization 8.95B 1.23B 98.52B
Net income 2021 1.41B 195M 15.56B Net income 2022 4.21B 581M 46.34B EV / Sales 2021 2.09 x
Net cash position 2021 1.85B 255M 20.33B Net cash position 2022 4.3B 594M 47.41B EV / Sales 2022 0.44 x
P/E ratio 2021
4.99 x
P/E ratio 2022
2.1 x
Employees 1,547
Yield 2021
6.08%
Yield 2022
9.08%
Free-Float 49.87%
More Fundamentals * Assessed data
Dynamic Chart
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Final Cash Dividend for Year 2023 CI
Tranche Update on Wuhan Easy Diagnosis Biomedicine Co.,Ltd.'s Equity Buyback Plan announced on March 28, 2024. CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. commences an Equity Buyback Plan for CNY 350 million worth of its shares, under the authorization approved on March 18, 2024. CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. authorizes a Buyback Plan. CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 06 June 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Approves Dividend for 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Proposes Profit Distribution for 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
China stocks retreat on concerns of surging COVID cases RE
China stocks retreat on concerns of rising COVID cases RE
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Announces Executive Elections CI
More news
1 day-1.61%
1 week-2.05%
Current month-10.06%
1 month-9.43%
3 months-1.95%
6 months-14.75%
Current year-14.71%
More quotes
1 week
19.23
Extreme 19.23
20.33
1 month
19.23
Extreme 19.23
22.33
Current year
14.81
Extreme 14.81
23.33
1 year
14.81
Extreme 14.81
33.17
3 years
14.81
Extreme 14.81
64.61
5 years
10.71
Extreme 10.7138
64.61
10 years
7.90
Extreme 7.8954
64.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 22/10/13
Director of Finance/CFO 40 17/08/21
Director/Board Member - 30/10/13
Members of the board TitleAgeSince
Director/Board Member 63 25/11/21
Director/Board Member 56 20/10/22
Chief Executive Officer 50 22/10/13
More insiders
Date Price Change Volume
26/04/24 19.59 -1.61% 4,054,983
25/04/24 19.91 -0.55% 1,817,909
24/04/24 20.02 -0.60% 2,001,954
23/04/24 20.14 +1.21% 2,702,892
22/04/24 19.9 -0.50% 1,840,194

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is a China-based company which is mainly engaged in research and development, manufacture and sales of Point of Care Testing (POCT) rapid diagnostic reagents and quick testing instruments. The Company's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The Company's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002932 Stock